AI assistant
4SC AG — Report Publication Announcement 2011
May 3, 2011
5_rns_2011-05-03_9fe69f59-297f-4667-9649-b04ce1f69ef3.html
Report Publication Announcement
Open in viewerOpens in your device viewer
News Details
Corporate | 3 May 2011 07:30
4SC AG: Q1 2011 Results Conference Call 10 May, 2011
4SC AG / Key word(s): Quarter Results
03.05.2011 / 07:30
Planegg-Martinsried, Germany, 3 May, 2011 – 4SC AG (Frankfurt, Prime Standard: VSC) a drug discovery and development company, will announce its results for the first quarter 2011 (ended 31 March, 2011) on 10 May, 2011. The senior management team will host a conference call at 3pm CET (9am EST) on the day to inform about the results for the quarter and all important developments in the reporting period.
Participants can access the conference under the following telephone numbers:
Date: 10 May, 2011
Time: 3pm CET (9am EST)
Dial-in numbers:
0800 10 12 072 (Germany)
0800 358 0886 (UK)
1-877-941-1469 (USA)
+49 (0) 6958 999 0804 (other countries)
Conference-ID: 4437460
Approximately two hours after the live presentation, an audio replay of the conference will be available on the 'investors' section of the homepage www.4sc.com .
About 4SC
4SC AG (ISIN DE0005753818) discovers and develops targeted small molecules for autoimmune and cancer indications. Vidofludimus (4SC-101), an IL-17 inhibitor, is currently in Phase II development in rheumatoid arthritis and inflammatory bowel disease (IBD), for which positive results from a Phase IIa study were recently reported. The company's lead oncology compound, resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma (most common form of liver cancer), Hodgkin's lymphoma and KRAS-mutant colorectal cancer. Two further oncology compounds, 4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.
Founded in 1997, 4SC has 94 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
For further information, please visit www.4sc.com .
For further information please contact:
Yvonne Alexander
4SC AG
Investor & Public Relations
Tel.: +49 (0) 89 70 07 63 – 66
End of Corporate News
03.05.2011 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
| Language: | English |
| Company: | 4SC AG |
| Am Klopferspitz 19a | |
| 82152 Martinsried | |
| Deutschland | |
| Phone: | +49 (0)89 7007 63-0 |
| Fax: | +49 (0)89 7007 63-29 |
| E-mail: | [email protected] |
| Internet: | www.4sc.de |
| ISIN: | DE0005753818 |
| WKN: | 575381 |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart |
| End of News | DGAP News-Service |
| - - - |
| 122510 03.05.2011 |